Tests NBI-1117570 against placebo in hospitalized adults with schizophrenia
Tests NBI-1117570 or a placebo in adults with schizophrenia needing hospital care.
Plain-language title generated from the registry record
Registry title: Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Key facts
- Where
- Bucharest, Jassi, and Târgu Mureş, RomaniaSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07288333, who can take part
Where in Romania
- Spitalul Clinic de Psihiatrie Prof Dr Alexandru ObregiaBucharest, RomaniaTaking people
- Institutul De Psihiatrie Socola IasiJassi, RomaniaTaking people
- Spitalul Clinic Judeţean MureşTârgu Mureş, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Neurocrine Biosciences
- Trial code
- NCT07288333EU 2025-521868-35-00
- Record updated
- 22 July 2026
- Original description
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.Read full original descriptionShow less
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Inclusion: 18 to 55 years of age; Primary diagnosis of schizophrenia ≥1 year before screening; Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before screening and currently requires hospitalization; Participant must have had a positive response to at least 1 antipsychotic therapy (other than clozapine) for the treatment of a prior acute relapse.
Exclusion: Currently taking prohibited medications; History of epilepsy, seizures, or convulsions; Has orthostatic hypotension, or history of pulmonary hypertension, obstructive coronary artery disease, hypertrophic cardiomyopathy, myocardial infarction, coronary artery revascularization, heart failure, left ventricular hypertrophy, moderate or severe cardiac valvopathy, or other cardiovascular conditions or measures that would preclude participation; Considered to be at imminent risk of suicide or injury to self or others; Pregnant or lactating; Note: Additional inclusion/exclusion criteria may apply, per protocol.